Buy 2-Fluorodeschloroketamine for sale online from USA vendor
Table of Contents
- Introduction
- Chemistry
- Pharmacology
- Subjective Effects
- Physical Effects
- Cognitive Effects
- Dosage
- Toxicity and Harm Potential
- Legal Status
2-Fl-2'-Oxo-PCM: An Introduction
2-Fl-2'-Oxo-PCM, also known as 2-Fluorodeschloroketamine (2-FDCK), is a relatively lesser-known dissociative substance belonging to the arylcyclohexylamine class. Chemically akin to ketamine and deschloroketamine (DCK), it shares structural similarities with these compounds. While it is believed to function as an antagonist to the NMDA receptor, the scientific understanding of its mechanisms remains limited due to restricted research in this domain.
Origins and Availability
The precise origins of 2F-DCK are not extensively documented. However, it emerged on the online research chemical market around 2017. Initially marketed as a legal alternative to ketamine, its introduction followed the success of deschloroketamine, a similar analog of ketamine.
Subjective Effects
Subjective experiences associated with 2F-DCK encompass a range of sensations:
Sedation and Motor Control Loss
Users commonly report feelings of sedation and loss of motor control akin to those induced by other dissociative substances.
Pain Relief
Anecdotal evidence suggests that 2F-DCK may offer relief from physical discomfort, though further research is warranted to substantiate this claim.
Internal Hallucinations and Conceptual Thinking
Internal hallucinations and alterations in conceptual thinking are frequently reported effects, indicating the substance's capacity to induce profound alterations in perception.
Euphoria and Dissociation
Euphoria, along with dissociation, is commonly experienced. Dissociation, a multifaceted mental state characterized by perceptual distortions and a sense of detachment from both the environment and oneself, is a hallmark effect of 2F-DCK.
Dose-Dependent Effects
Similar to ketamine, the effects of 2F-DCK are highly dose-dependent. Lower doses may elicit effects resembling alcohol intoxication, whereas higher doses can induce hallucinogenic states often referred to as a "k-hole," characterized by profound dissociation and out-of-body experiences.
Pharmacology, Metabolism, and Toxicity
Despite its usage, comprehensive data on the pharmacological profile, metabolism, and toxicity of 2-FDCK remain scarce. Given its brief history of human consumption, caution is warranted.
Harm Reduction Practices
Given the limited understanding of its effects and risks, it is strongly advised to employ harm reduction practices when using 2F-DCK or any similar substances. This includes cautious dosing, testing for purity, and ensuring a safe environment conducive to minimizing potential harm.
In summary, while 2-Fl-2'-Oxo-PCM holds promise for research and therapeutic applications, its potential risks and effects necessitate further exploration and responsible usage practices.
Chemistry
Molecular Structure
2-Fluorodeschloroketamine (2-FDCK), chemically known as 2-(2-Fluorophenyl)-2-methylamino-cyclohexanone, belongs to the arylcyclohexylamine class of drugs. This class is characterized by structures containing a cyclohexane ring bonded to an aromatic ring, accompanied by an amine group. Specifically, 2-FDCK comprises a phenyl ring linked to a cyclohexane ring bearing a ketone group (cyclohexanone). An amino methyl chain (-N-CH3) is attached to the adjacent alpha carbon (R2) of the cyclohexanone ring. Additionally, the phenyl ring is substituted with a fluorine group at R2.
Chirality
2-Fluorodeschloroketamine is a chiral molecule commonly produced as a racemate. The prefix "des-" in its name signifies the absence of a functional group (in this case, "chloro"), distinguishing it from ketamine, which contains chlorine at the corresponding position.
Pharmacology
Mechanism of Action
Due to limited research, understanding of 2-FDCK's pharmacology primarily relies on its structural resemblance to other arylcyclohexylamine dissociatives like DCK and ketamine. It is hypothesized to function as an antagonist to the NMDA receptor.
NMDA Receptor Antagonism
NMDA receptors facilitate the transmission of electrical signals between neurons in the brain and spinal cord. Activation of these receptors requires them to be open. Dissociatives like 2-FDCK induce closure of NMDA receptors by blocking them. Consequently, neuronal disconnection occurs, resulting in sensations such as numbness, impaired movement, and potentially the characteristic "K-hole" experience associated with this substance.
Subjective Effects
Disclaimer: The subjective effects described below are based on anecdotal reports from users and the Subjective Effect Index (SEI). It is essential to approach these effects with caution, as they may not manifest consistently and can vary based on dosage and individual factors. Higher doses are more likely to produce the full spectrum of effects, including potential adverse reactions such as addiction, severe injury, or fatality.
Physical Effects of 2-Fluorodeschloroketamine (2-FDCK)
Pain Relief
2-FDCK is reported to offer relief from physical discomfort, potentially acting as an analgesic.
Spontaneous Physical Sensations
Users may experience spontaneous physical sensations, which can vary widely and include tingling, warmth, or numbness.
Physical Euphoria
Feelings of physical euphoria can accompany the use of 2-FDCK, contributing to its subjective effects.
Dizziness
Dizziness is a common physical effect associated with the use of 2-FDCK.
Motor Control Loss
Users often experience a loss of motor control, which can manifest as difficulty coordinating movements or impaired balance.
Nausea
Nausea may occur as a side effect of using 2-FDCK, particularly at higher doses.
Perception of Bodily Lightness
Some individuals report a sensation of bodily lightness, feeling as though they are floating or weightless.
Physical Autonomy
The sense of physical autonomy may be altered, leading to feelings of detachment from the body or a sense of disconnection from physical sensations.
Spatial Disorientation
Spatial disorientation, characterized by difficulty in perceiving one's position in space, can occur with 2-FDCK use.
Tactile Suppression
Users may experience suppression of tactile sensations, leading to reduced sensitivity to touch.
Orgasm Suppression
2-FDCK may suppress or inhibit the ability to achieve orgasm in some individuals.
Disconnective Effects
Tactile Disconnection
A disconnective effect, users may experience a diminished sense of touch or a feeling of separation from tactile sensations.
Visual Disconnection
Progressive visual disconnection can lead to the onset of the "k-hole" experience, characterized by perceptual distortions and hallucinatory states. This may include sensations of voids, spaces, and alterations in visual perception.
Consciousness Disconnection
Users may experience a disconnection from consciousness, leading to altered states of awareness and dissociation.
Visual Effects
Suppression
Visual suppression may occur, leading to a decrease in the clarity or intensity of visual perception.
Double Vision
Double vision, or diplopia, may occur, causing overlapping or duplicated images.
Frame Rate Suppression
Users may perceive a reduction in the frame rate of visual perception, resulting in a sense of slowed or disjointed visual processing.
Pattern Recognition Suppression
The ability to recognize patterns or distinguish visual stimuli may be impaired.
Visual Acuity Suppression
Visual acuity, or sharpness of vision, may be diminished.
Distortions
Various visual distortions may occur, including alterations in shape, size, or color of objects.
Environmental Cubism
Users may perceive the environment as fragmented or distorted, resembling the style of cubist art.
Environmental Orbism
Visual distortions may include the perception of spherical or orb-like shapes within the environment.
Perspective Distortions
Distortions in perspective can lead to a warped or altered perception of depth and distance.
Scenery Slicing
The visual environment may appear fragmented or sliced, with discontinuities in perceived space.
Geometry
Geometric patterns and shapes may be perceived, often with intricate and detailed visual effects.
Hallucinatory States
2-FDCK use may induce hallucinatory states, including internal hallucinations involving autonomous entities, landscapes, and complex scenarios.
In summary, the physical effects of 2-Fluorodeschloroketamine encompass a wide range of sensations and perceptual alterations, contributing to its dissociative and hallucinogenic properties. These effects should be approached with caution, considering the potential for altered states of consciousness and impaired physical function.
Cognitive Effects of 2-Fluorodeschloroketamine (2-FDCK)
Comparison to Ketamine
The cognitive effects of 2-FDCK closely resemble those of ketamine, with some users finding them nearly indistinguishable. However, there are subtle differences noted by some individuals.
Slower Paced Experience
Subjectively, the experience on 2-FDCK tends to be paced at a slower rate compared to ketamine, accompanied by distinct psychedelic effects unique to 2-FDCK.
Difficulty "Holing"
Some users report that 2-FDCK can occasionally induce slightly more confusion and difficulty reaching the "k-hole" state at higher dosages compared to ketamine. However, opinions on this aspect vary among users.
Antidepressant Effects
Many users note that 2-FDCK retains the same antidepressant effects as ketamine, contributing to its potential therapeutic applications.
Cognitive Effects
- Anxiety Suppression: Users may experience a reduction in feelings of anxiety or tension.
- Compulsive Redosing: Some individuals may exhibit compulsive behavior related to redosing the substance.
- Conceptual Thinking: 2-FDCK can enhance conceptual thinking, leading to novel ideas or perspectives.
- Creativity Enhancement: Creativity may be enhanced under the influence of 2-FDCK.
- Déjà Vu: The sensation of déjà vu, or the feeling of having experienced something before, may occur.
- Depersonalization and Derealization: Users may feel a sense of detachment from themselves (depersonalization) or from their surroundings (derealization).
- Disinhibition: Inhibition may be reduced, leading to more spontaneous or uninhibited behavior.
- Dream Potentiation: Dreams may become more vivid or intense.
- Cognitive Euphoria: Feelings of euphoria may extend to cognitive processes, leading to a heightened sense of well-being.
- Immersion Enhancement: The sense of immersion in activities or experiences may be enhanced.
- Analysis Suppression: Critical thinking and analytical abilities may be diminished.
- Introspection: 2-FDCK can facilitate introspective experiences, leading to deep self-reflection.
- Memory Suppression: The substance may impair short-term memory formation.
- Ego Death: Users may experience a dissolution or loss of the sense of self, known as ego death.
- Amnesia: Episodes of memory loss or gaps in recollection may occur.
- Time Distortion: The perception of time may become distorted, with moments seeming to stretch or contract.
- Thought Deceleration: Cognitive processes may slow down, leading to a more contemplative state.
- Increased Music Appreciation: Users may perceive music as more profound or emotionally resonant.
Auditory Effects
- Distortions: Auditory perception may be distorted, leading to alterations in the way sounds are perceived.
- Hallucinations: Auditory hallucinations, such as hearing voices or sounds that are not present, may occur.
- Suppression: Auditory perception may be suppressed, leading to a reduced sensitivity to sounds.
In summary, the cognitive effects of 2-Fluorodeschloroketamine encompass a broad range of experiences, including both positive and potentially challenging effects. Users should approach the substance with caution and be mindful of its potential impact on cognitive function and mental well-being.
Dosage of 2-Fluorodeschloroketamine (2-FDCK)
Threshold
- Threshold Dose: 5 mg
- At this dosage level, users may begin to perceive subtle effects of 2-FDCK, although they may not be fully pronounced.
Light
- Light Dose: 10 - 25 mg
- A light dose of 2-FDCK typically induces mild to moderate effects, providing a gentle introduction to its psychoactive properties.
Common
- Common Dose: 25 - 70 mg
- Within this dosage range, users can expect to experience the typical effects of 2-FDCK, including dissociation and alterations in perception. This range is suitable for recreational use for many individuals.
Strong
- Strong Dose: 70 - 140 mg
- A strong dose of 2-FDCK can lead to intense dissociative effects, profound alterations in consciousness, and potentially immersive hallucinatory experiences.
Heavy
- Heavy Dose: 140 mg+
- At doses exceeding 140 mg, users may experience overwhelming dissociation and hallucinations, potentially leading to states of ego dissolution or profound disconnection from reality. This dosage level is not recommended for inexperienced users and should be approached with extreme caution.
It's important to note that individual sensitivity to 2-FDCK can vary, and factors such as body weight, tolerance, and overall health can influence the effects of the substance. Users are advised to start with a lower dose and gradually titrate upwards to assess their tolerance and response to the compound. Additionally, harm reduction practices, such as using accurate measuring tools and having a trusted individual present, should be employed to minimize the risk of adverse effects.
Toxicity and Harm Potential of 2-Fluorodeschloroketamine (2-FDCK)
Limited Scientific Study
The toxicity and long-term health effects of recreational 2-FDCK use have not been extensively studied in scientific contexts. As a result, the exact toxic dosage and potential risks remain unknown.
Anecdotal Evidence
Anecdotal reports from individuals within the community suggest that low to moderate doses of 2-FDCK used sparingly do not typically lead to negative health effects. However, caution should always be exercised, and harm reduction practices should be employed.
Harm Reduction
It is strongly recommended to practice harm reduction strategies when using 2-FDCK or any similar substances. This includes accurate dosing, testing for purity, and creating a safe environment for consumption.
Dependence and Abuse Potential
2-FDCK, like other NMDA receptor antagonists, can be moderately addictive with a high potential for abuse. Chronic use may lead to psychological dependence, cravings, and withdrawal effects upon cessation.
Tolerance
Tolerance to the effects of 2-FDCK develops with prolonged and repeated use. Users may find themselves requiring increasingly larger doses to achieve the desired effects. However, tolerance can diminish over time with abstinence from the substance.
Urinary Tract Effects
Repeated and excessive use of 2-FDCK may lead to bladder and urinary tract problems, similar to those observed with ketamine but potentially to a lesser extent. Symptoms can include urinary frequency, urgency, pressure, pain, hematuria, and incontinence. These effects can be mitigated by limiting the frequency and dosage of 2-FDCK use.
Dangerous Interactions
Combining 2-FDCK with certain substances can lead to dangerous or life-threatening outcomes. Some substances, such as benzodiazepines, alcohol, opioids, and MAOIs, can potentiate the effects of 2-FDCK, increasing the risk of respiratory depression, loss of consciousness, and other adverse effects.
Legal Status
Various Countries' Legal Status
- Austria: Illegal under the Neue-Psychoaktive-Substanzen-Gesetz Österreich.
- Canada: Not specifically listed but could be considered controlled under Schedule I of the Controlled Drugs and Substances Act.
- Germany: Controlled under the NpSG (New Psychoactive Substances Act).
- Italy: Classified as a Schedule I controlled substance.
- Latvia: Illegal.
- Switzerland: Controlled substance under Verzeichnis E.
- Turkey: Illegal to possess, produce, supply, or import.
- United Kingdom: Class B drug under the Misuse of Drugs Act.
It's crucial to be aware of the legal status of 2-FDCK in your country and to comply with relevant laws and regulations.
Frequently Asked Questions (FAQ)
1. What is 2-Fluorodeschloroketamine (2-FDCK)?
2-Fluorodeschloroketamine, also known as 2-FDCK, is a dissociative substance belonging to the arylcyclohexylamine class. It shares similarities with ketamine and is believed to act as an NMDA receptor antagonist.
2. What are the subjective effects of 2-FDCK?
Subjective effects of 2-FDCK include sedation, motor control loss, pain relief, internal hallucinations, conceptual thinking, euphoria, and dissociation.
3. What are the physical effects of 2-FDCK?
Physical effects of 2-FDCK may include pain relief, spontaneous physical sensations, dizziness, motor control loss, nausea, and spatial disorientation, among others.
4. What are the cognitive effects of 2-FDCK?
Cognitive effects of 2-FDCK may include anxiety suppression, conceptual thinking, creativity enhancement, memory suppression, time distortion, and increased music appreciation.
5. What is the recommended dosage of 2-FDCK?
Dosages of 2-FDCK vary depending on the desired effects. A threshold dose is around 5 mg, while a heavy dose may exceed 140 mg. It's essential to start with a lower dose and titrate upwards cautiously.
6. Are there any toxicity or harm potential associated with 2-FDCK?
The long-term health effects of 2-FDCK are not well-studied, but anecdotal evidence suggests limited negative effects at low to moderate doses. However, chronic use may lead to dependence, tolerance, and urinary tract issues.
7. What should I know about the legal status of 2-FDCK?
The legal status of 2-FDCK varies by country. It may be illegal to possess, produce, sell, or import in some jurisdictions. It's important to be aware of and comply with relevant laws and regulations.
These answers provide a brief overview of commonly asked questions about 2-Fluorodeschloroketamine. For more detailed information, refer to the respective sections of the article.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics